


The Molecular Screening and Therapeutics in Leukaemia and Lymphoma Study (MoST-LLy) General Information Sheet

Chief Investigator	Prof Steven Lane (Clinical Lead)
Project Managers	Gerlinda Amor, Helen Christensen
Contact details for queries:	Phone: (07) 3845 3766 or 0487 400 607 Email: mostlly@qimrb.edu.au

What is the MoST-LLy Study?

The MoST-LLy study is looking at new ways to test blood cancers using advanced genetic and molecular testing. The goal is to learn more about each person's cancer and see whether this information can help identify treatment options that may be suitable for them..



If you agree to take part in the study, your blood cancer sample may be tested using one or more advanced methods, including gene panel testing, whole exome sequencing (WES), whole genome sequencing (WGS), or whole transcriptome sequencing (WTS).

These tests look for changes in the cancer that may help doctors better understand it and identify treatments that could be helpful.

After testing, a report is sent to your haematologist that includes:

- (i) Important genetic or molecular changes found in the cancer.
- (ii) Possible treatment options that may be suitable for you, such as a clinical trial, targeted therapy, or other personalised treatment.

Who can take part?

The MoST-LLy program is for people aged 18 years and older with a blood cancer who meet the study requirements.

How can a patient join the MoST-LLy Program?

If you are interested in the study, talk to your haematologist. Your haematologist can check whether you are eligible and, if appropriate, refer you to the study using a secure online referral form. The referral includes information about your blood cancer and a pathology report to help the study team arrange testing.

For more information about the MoST-LLy study, visit:

<https://www.qimrb.edu.au/studies/most-llly-study>



The ethical aspects of this study have been approved by the HREC of Metro South Health EC00167 (HREC/2024/QMS/113451).

This study is made possible through the support of the Leukaemia Foundation of Australia, Tour de Cure and an MRFF Grant with CIA Prof Steven Lane.